Searched for
DRUG AFFORDABILITY INDIA
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- 6 years after Sushant Singh Rajput's death, Rhea Chakraborty revisits darkest phase of her life. Why Aryan Khan's case triggered herSix years after the death of Sushant Singh Rajput, Rhea Chakraborty has opened up about the emotional scars left by the controversy that fo...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Good news for diabetes & BP patients: Govt cuts prices of these 30 medicines, relief may reach pharmacies soonThe National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 essential drug formulations, including those for diabet...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Out-of-pocket expenditure share declines by 21 percentage points from 2013-14: Health ministryGovernment health spending has risen, leading to a significant drop in out-of-pocket health expenses. This decline, from 64.2% in 2013-14 t...
- PSU closure: Govt sets in motion new move after years wasted in stop-start processThe Centre is pushing ministries to accelerate the closure of unprofitable state-owned companies. Progress has been slow despite a policy a...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...
- AbbVie loses patent plea for Hep C drugThe Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to aff...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in CanadaDr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...
- Roche brings 7-minute lung cancer shot to IndiaRoche Pharma India introduces a new injectable immunotherapy for lung cancer. This treatment takes only seven minutes, a significant reduct...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- India should chart own path in treatment of rare diseases: ICMR chiefIndia is taking a groundbreaking step forward in the realm of rare disease care with a distinctive approach that champions local ingenuity ...
- India supplies 20% of global generic medicines; its IP rules WTO-compliant: GTRIIndia is a major global supplier of affordable generic medicines. The United States continues to pressure India regarding intellectual prop...
- Compliance squeeze, global scrutiny redefine India’s $30 billion pharma export playbookAs global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Funding for innovations key for India to remain vaccine leader: Cyrus PoonawallaSpeaking to ET after receiving the Lifetime Achievement Award for 2025 as part of the ET Awards for Corporate Excellence, Cyrus Poonawalla,...
Load More
